Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S; AcromegalyConsensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8. doi: 10.1210/jc.2009-2670.
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2012 Aug 18. [Epub ahead of print]
KatznelsonL, AtkinsonJL, CookDM, EzzatSZ, HamrahianAH, MillerKK; AACEAcromegalyTaskForce. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 update: executivesummary. EndocrPract. 2011 Jul-Aug;17(4):636-46.
RonchiCL, BoschettiM, DegliUbertiEC, MariottiS, GrottoliS, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M; Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.ClinEndocrinol (Oxf). 2007 Oct;67(4):512-9.
Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. JClinEndocrinolMetab.2007Jan;92(1):180-5.
Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10.
Caron P, Bevan J, Clermont A, MaisonobeP. Early and sustained tumour volume reduction and GH/IGF1 control in patients with GH-secreting pituitary macroadenoma primarily treated with lanreotide Autogel 120 mg for 48 weeks: the PRIMARYS study. The 15th European congress of Endocrinology, 2013
Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary.2010;13(1):18-28.
Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.Clin Endocrinol (Oxf). 2008 Mar;68(3):473-80.
Croxtall JD, Scott LJ. LanreotideAutogel: a review of its use in the management of acromegaly. Drugs. 2008;68(5):711-23.
Murray RD, Melmed S. A criticalanalysis of clinicallyavailablesomatostatinanalogformulations for therapy of acromegaly.JClinEndocrinolMetab. 2008 Aug;93(8):2957-68. doi: 10.1210/jc.2008-0027.
Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.ClinEndocrinol (Oxf). 2006 Sep;65(3):320-6.
Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plöckinger U, Petersenn S; German Lanreotide Study Group. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):156-62.
Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, Davis JR, Howlett TA, Randeva HS, Stewart PM, Viswanath A. Homeadministration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008 Mar;68(3):343-9.
Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.Clin Endocrinol (Oxf). 2006 Feb;64(2):209-14.
Gutt B., Bidlingmaier M., Kretschmar K., et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005; 113(3):139-44.
Florio T., Thellung S., Corsaro A., et al. CharacterizationoftheintracellularmechanismsmediatingsomatostatinandlanreotideinhibitionofDNAsynthesisandgrowthhormonereleasefromdispersedhumanGH-secretingpituitaryadenomacellsinvitro. Clin Endocrinol (Oxf) 2003. 59:115-28.
WaskoR, JankowskaA, KotwickaM, LiebertW, SowinskiJ, WarcholJB. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas.NeuroEndocrinolLett. 2003 Oct;24(5):334-8.
Alexopoulou O., Abrams P., Verhelst J., et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004; 151:317-24.
Attanasio R., Lanzi R., Losa M., et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008; 14(7):846-55.
Baldelli R., Ferretti E., Jaffrain-Rea M., et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999; 84:527–32.
Hradec J., Krai J., Janota T., et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999; 83:1506-9.
Lombardi G., Colao A., Marzullo P., et al. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002; 25(11):971-6.
Magyar D.M., Marshall J.R. Pituitarytumorsandpregnancy. Am J Obstet Gynecol 1978; 132:739-751.